# Dr. Reddy's Laboratories (RDY)

Sector: Generic pharmaceuticals

| Field | Value |
|---|---|
| Price | $14.90 |
| Market cap | $12B |
| Intrinsic value source | Analysts |
| Data as of | 2026-11-20 |
| Next earnings | 2027-01-20 (estimate) |

Analysts: Leaning bullish

Picks: Research only

Discount category: Far above intrinsic value

## In short

The market doubts that the Hyderabad generics maker can replace its lost lenalidomide profit after a quality problem stopped semaglutide, and steady semaglutide and biosimilar launches through 2027 can lift its value.

## Themes and gap

- Themes: Weight-loss drugs (weight-loss-drugs), Regulation and courts (regulation-legal)
- Gap type: Can close (closable)
- Why: The Q3 fiscal 2027 report, expected in late January 2027, and the return of semaglutide supply show whether new products replace the lenalidomide profit.

## About

Dr. Reddy's Laboratories Limited (Dr. Reddy's) is based in Hyderabad, India. It makes and sells generic medicines, branded generics, biosimilars, nicotine replacement therapy products and active pharmaceutical ingredients. Its largest segment is Global Generics, with sales in North America, Europe, India and emerging markets such as Russia. Its other segment, Pharmaceutical Services and Active Ingredients, includes the contract development and manufacturing company Aurigene Pharmaceutical Services. It reports under IFRS in Indian rupees. Revenues were Rs.335,933 million in fiscal 2026, the year that ended on March 31, 2026, and Rs.86,708 million in Q2 fiscal 2027. The equity shares trade in India on the BSE and NSE, and American Depositary Shares trade on the NYSE in US dollars. One ADS represents one equity share. Dr. Reddy's files 20-F and 6-K reports.

## Thesis

The price of Dr. Reddy's depends on whether new products can replace the profit from generic lenalidomide in the United States. North America revenues fell 23% in Q2 fiscal 2027 and 29% in the first half, mostly because lenalidomide sales fell, and the gross margin fell to 49.4% in the first half from 55.8%. For the price to rise, three things must be true. Generic semaglutide, which was approved in 10 countries by October 23, 2026 and in Brazil on November 5, 2026, must reach patients after the company fixes the problem with the active ingredient that caused a provision of Rs.2,397 million in Q1 fiscal 2027. Biosimilars, such as rituximab in the United States, and new launches in India and emerging markets must keep growing. The USFDA closed its inspection of the Bachupally formulations plant as Voluntary Action Indicated on November 14, 2026, and it must also close its observations at the API plant in Mexico without a warning letter. The Q3 fiscal 2027 report, expected in late January 2027, is the next test. If semaglutide supply stays stopped or US generic prices fall, profit can stay low for longer.

## Checkpoints

- Jan 20, 2027 (estimate): Q3 fiscal 2027 results. Status: Pending. Watch: North America revenues grow from Q2 and the EBITDA margin stays at about 20% or more, and this passes; a lower margin or falling North America revenues fail.
- Q1 2027 (estimate): Semaglutide supply resumes. Status: Pending. Watch: Dr. Reddy's says that semaglutide supply resumed in its approved markets, and this passes; a further delay or a recall fails.
- May 2027 (estimate): Fiscal 2027 results. Status: Pending. Watch: Profit for the second half of fiscal 2027 is above that of the first half, and this passes; a lower second half fails.

## Balance sheet

- Cash: ₹86.7B
- Debt: ₹72.3B
- Net cash: ₹14.4B

At September 30, 2026, Dr. Reddy's had cash and cash equivalents and other investments of Rs.86,670 million and loans and borrowings of Rs.72,287 million, so it had net cash of about Rs.14,383 million. Borrowings rose from Rs.58,539 million at September 30, 2025. Equity was Rs.389,370 million. At the release's convenience rate of Rs.95.83 per US dollar, cash and investments were about $904 million and borrowings about $754 million.

As of 2026-09-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/1135951/000157587226000725/rdy0952_ex99-2.htm

## Dividends

- Dividend yield: 0.6% (last 12 months, at the current price)
- Paid per share, last 12 months: $0.083 (1 payment)
- Current annual rate: $0.083 ($0.083 x 1 a year)
- Latest ex-dividend date: 2026-07-24, $0.083 per share
- Growth from 2020 to 2025: 6.6% a year
- Growth from 2016 to 2025: 4.9% a year

Dividends per share by year: 2016: $0.0594, 2017: $0.062, 2018: $0.0594, 2019: $0.0574, 2020: $0.066, 2021: $0.1356, 2022: $0.153, 2023: $0.1952, 2024: $0.0958, 2025: $0.091.

Source: company filings and market data, read on 2026-11-12.

## Recent events

- 2026-11-14: The USFDA classified the GMP inspection of the FTO-3 formulations plant in Bachupally, Hyderabad, which Dr. Reddy's reported on August 14, 2026, as Voluntary Action Indicated, and it closed the inspection.
- 2026-11-05: Brazil's National Health Surveillance Agency (ANVISA) gave Dr. Reddy's marketing authorization for generic semaglutide injection for adults with type 2 diabetes.
- 2026-10-28: The USFDA classified the July 2026 inspection of FTO-SEZ Process Unit-02 at Srikakulam, Andhra Pradesh, as Voluntary Action Indicated.
- 2026-10-23: Dr. Reddy's reported Q2 fiscal 2027 results. Revenues were Rs.86,708 million, down 1.5% from a year earlier and up 7.4% from Q1. EBITDA was Rs.17,828 million, or 20.6% of revenues, and profit attributable to equity holders was Rs.9,250 million. North America revenues fell 23%, mostly because of lower lenalidomide sales, while India grew 17% and Emerging Markets grew 24%.
- 2026-10-23: In Q2 fiscal 2027, Dr. Reddy's got USFDA approval for a rituximab biosimilar, launched sugammadex injection first to market in the United States and said that some batches of semaglutide failed specification because of a problem with the active ingredient. It also received a Form 483 with four observations at its FTO-3 plant in Bachupally, Hyderabad.
- 2026-10-21: The Drugs Controller General of India approved Zytorvi (toripalimab) for advanced esophageal squamous cell carcinoma, its second approved use in India.

## Latest news and filings

- Last earnings: 2026-10-23
- Next earnings: 2027-01-20 (expected; the company has not confirmed it)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-05-29 | 20-F | Annual report for the period ended Mar 31, 2026 | 2026-03-31 |  | https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm |
| 2025-06-06 | 20-F | Annual report for the period ended Mar 31, 2025 | 2025-03-31 | rdy-20250331 | https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/rdy-20250331.htm |

Every filing on SEC EDGAR (CIK 1135951): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001135951&type=&dateb=&owner=include&count=40

## Risks

- High: The profit from generic lenalidomide in the United States is going away. North America revenues were Rs.46,938 million in the first half of fiscal 2027, against Rs.66,531 million a year earlier.
- High: Semaglutide is the largest new product, and some batches failed specification because of the active ingredient. Supply must resume, and many generic makers can enter the same markets and cut prices.
- Medium: USFDA inspections can delay approvals. In 2026 the company received a Form 483 with four observations at FTO-3 in Bachupally and a Form 2953 with two observations at its API plant in Mexico. The USFDA closed the FTO-3 inspection as Voluntary Action Indicated on November 14, 2026.
- Medium: Russia revenues were Rs.10.1 billion in Q2 fiscal 2027, so sanctions or the rouble can change results. The company reports in rupees, so the ADS price in dollars also moves with the rupee.
- Low: Generic prices in Europe fall, and nicotine replacement therapy revenues fell 6% in Q2 fiscal 2027.

## Links

- Page: https://picks.utilarium.app/company/RDY/
- History of changes: https://picks.utilarium.app/company/RDY/history/
- JSON with full history: https://picks.utilarium.app/data/company/RDY.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
